Abstract
INTRODUCTION
Interferon is considered to be one of the treatments for many diseases. However, interferon therapy is associated with side effects, the most common being general sym ptoms such as fever, weight loss and headache. Some studies have demonstrated cardiac adverse effects of interferon for chronic hepatitis C (CHC) [1, 2] . Most frequently reported are arrhythmia, congestive heart failure and sudden death. Reported with rarer frequency are poly neuropathy, paranoia and suicidal thoughts, diabetes mellitus, retinopathy, optical neuritis, diminution of hearing, seizures, loss of libido and cardio toxicity [3] . Recently some reports demonstrated acute pericarditis complicating inter feron therapy [412] . We conducted a review of "interferon related pericarditis".
MATERIALS AND METHODS

Selection of case reports
We searched MEDLINE, EMBASE, Cinahl, and the Co chrane Database from the earliest available date through September 2016. A search strategy using the Medical Subject Headings and text keywords "interferon" and "pericarditis" were used. The retrieved studies were manually screened to assess their appropriateness for this study. All references cited in the studies were also reviewed to identify additional published articles not indexed in the database. The search was not restricted by language.
RESULTS
Patients
Nine case reports were eligible for the present study; seven were in English [4, 5, 7, 8, 1012] and two in French [6, 9] . Clinical characteristics of patients are shown in Table 1 . Six of 8 cases were women and the mean age was 43.8 ± 13.8 years with CHC in 6 cases, malignant melanoma in 2 cases and chronic myelogenous leukemia in 1 case. The patients complained of chest pain in 6 cases, dyspnea in 5 cases and edema in 2 cases. Pericardial friction rub was heard in 3 of 9 cases [5, 8, 9] . Congestive heart failure occurred in 3 of 9 cases [810] . Two mechanisms for pericarditis were demonstrated, one is autoimmune included lupus like syndrome (AI group) in 2 cases and the other is cardio toxicity (CT group) in 4 cases. Three of 9 articles didn't mention the mechanisms for pericarditis.
Clinical history
Three cases had clinical history. The 28yearold patient had allergic asthma since infancy [4] . The 24yearold woman following therapy with interferon α was diagnosed with systemic lupus erythematosus (SLE), and she was treated with prednisone (40 mg/d) [5] . When prednisone had been stopped completely for 3 mo, a pericarditis occurred. The patient had a recurrence of SLE. The 63yearold man was diagnosed as diffuse large B cell nonHodgkin's lymphoma and was treated with a full course of chemotherapy consisting of cyclophosphamide, adriamycin, vincristine and dexamethasone [8] .
Laboratory findings
The woman with SLE [5] experienced four episodes of fever and pain in the left shoulder while breathing. Anti nuclear antibody and antids DNA antibody tests were negative, whereas circulating immune complexes were positive at the second and the third episode. CH50 and C4 levels were decreased with slightly elevated C3d level. Laboratory results of the 63yearold man with non Hodgkin's lymphoma presented antinuclear antibodies (titer 1/40) [8] .
The blood sample examination of the 67yearold man with CHC showed antiDNA antibody and antids DNA IgM were positive [10] . Figure 1 showed a relationship between the daily dose of interferon and the duration of treatment with interferon. Autoimmune due to interferon does not dependent on the daily dose but developed within one month with interferon treatment. Cardio toxicity due to interferon does not dependent on the daily dose or the duration of treatment with interferon.
Interferon daily dose and duration of treatment with interferon
Chest radiography
Chest radiography demonstrated abnormalities in three cases. Chest Xray of the 63yearold man showed an enlarged heart silhouette and bilateral pleural effusion [8] . Chest radiograph of the 53yearold woman showed cardiomegaly [9] . Portable chest radiograph of the 67year old man revealed pulmonary vascular congestion without pleural effusion [10] .
Electrocardiogram
Electrocardiogram (ECG) demonstrated abnormality in one case. ECG showed gradual STsegment elevation in leads V1 through V6 without elevated myocardial enzyme in the 67yearold man [10] . Coronary angiography showed that there was no significant coronary arterial stenosis in this case.
Ultrasound cardiology
Ultrasound cardiology (UCG) demonstrated pericardial effusion in 7 of 9 cases; mild in 2 cases [6, 12] , moderate in 2 cases [4, 10] , severe in 1 case [9] , and no presentation in 2 cases [7, 11] . The 53yearold female was diagnosed with con structive pericarditis with pretamponade [9] .
Re-start and re-challenge test
The interferon treatment was restarted in three cases [4, 6, 11] . The 28yearold patient suffered a pericarditis relapse at seven months after resumption of interferon α therapy [4] . The 42yearold female felt chest pain, after 7 h from administration of 1 million interferon α [6] . After the first dose of interferon administration symptoms reappeared and UCG showed an increase of pericardial fluid in the 38yearold female [11] . Rechallenge test was performed in one case [12] . Within ten hours of the reinitiation of interferon therapy, the 39yearold woman developed chest pain identical to her previous pain.
Complications
Two cases developed other complications. An electro myography showed signs of polyneuropathy in the 40year old female [7] . The 67yearold man developed chronic inflammatory demyelinating polyneuropathy during treat ment with pegylated interferon2a for chronic active hepatitis C viral infection [10] .
Treatment
Treatment of druginduced cardio toxicity rests mainly on early recognition and drug discontinuation. Interferon treatment was stopped in 7 of 9 cases. Four of 9 cases were treated with prednisone from 10 mg per day to 50 mg/d [4, 5, 8, 10] and 4 with nonsteroidal antiinflammatory drugs (NSAIDs) [5, 7, 11, 12] . All of the AI group was treated with prednisone [5, 10] and two of the CT group were treated with NSAIDs [7, 11] and one of the CT group dexamethasone [8] . The 53yearold female was treated with medications of antituberculosis, but died because multiple organ failure [9] . Figure 2 showed an algorithm of the suspected interferon related pericarditis management.
DISCUSSION
Cardiac adverse effects of interferon α for CHC have been demonstrated [1, 2] . Most frequently reported are arrhythmias, congestive heart failure and sudden death. These side effects occurred during treatment with in terferon α. However, pericarditis as a side effect of treat ment with interferon is rare.
In 1988, the first report concerning interferon related pericarditis was presented by anonymity [13] . This report demonstrated two patients with continuous interferon therapy for chronic myelogenous leukemia had severe side effects consisting of pleural effusions and pericarditis. Montastruc et al [14] presented that there was an isolated pericarditis for which it was necessary to interrupt the interferon α treatment. However, these two articles didn't describe in detail. Consequently, 9 articles were enrolled in the present study. Two mechanisms for pericarditis were demonstrated, one is autoimmune in 2 articles and Fava et al [4] 28/NA CML IFNα 13 mo NA Boonen et al [5] 24/F CHC IFNα 1 mo Autoimmune Wisniewski et al [6] 42/F CHC IFNα 6 h Cardio toxicity Gressens et al [7] 40/F CHC IFNα2b 3 mo Cardio toxicity Benjamini et al [8] 63/M MM IFNα2b 1 mo Cardio toxicity Hamdani et al [9] 53/F CHC PEG IFN α2a 6 mo NA Nishio et al [10] 67/M CHC PEG IFN 2a 15 d Lupus like syndrome Popescu et al [11] 38/F CHC PEG IFN 2a 7 mo Cardio toxicity Ashraf et al [12] 39/F MM IFNα 1 d NA the other is cardio toxicity in 4 articles. Three of 9 articles didn't mention the mechanisms for pericarditis. Prospective study reported on autoimmune pheno mena in 987 patients treated with interferonα for CHC. Twelve patients developed hyperthyroidism, 6 hypo thyroidism, 3 interstitial pneumonia, 1 SLE, 2 rheumatoid arthritis, 2 autoimmune hepatitis and 1 autoimmune thrombocytopenic purpura [15] . In the present study, the appearance of lupuslike syndrome by the interferon treatment has been reported in 1 article and autoimmune in 1 article. The mechanism by which interferon α induces autoimmune mediated complications is largely unknown. However, interferon alpha induses numerous target genes in antigenpresenting cells (APCs), such that APCs are stimulated and enhance humoral autoimmunity, promote isotype switching, and potently activate autoreactive T cells. Moreover, interferon alpha can synergistically amplify T cell autoreactivity by directly promoting Tcell activation and keeping activated T cells alive. Via the latter mechanisms, interferon can trigger autoimmune diseases [16] . There is a possibility that interferon may damage endothelial cells, cause the thickening of capillary walls, and induce deposition of immune complexes. Interferon evokes the release of several cytokines, including tumor necrosis factor alpha, and interleukins 2, 6 and 1, affecting autonomic sympathetic nerve activity and vasopressor responses [17] . Interferon induces an autoimmune reaction through various mechanisms including production of gamma globulins and interleukin6 (IL6) [18] and inhibition of Allospecific suppressor T lymphocytes, as well as activation of natural killer cells [19] . IL6 was significantly increased in pericardial effusion [20] . Interferon has been associated with exacerbation or induction of a wide variety of clinical and serological immune disorders, including systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, thyroid disease and diabetes mellitus. On the other hand, Orságová et al [21] demonstrated that positivity of antinuclear antibodies and smooth muscle antibodies or increased rheumatoid factor and circulating immune complexes are often found in patients with chronic hepatitis B and CHC treated with interferon, but their presence does not correlate with the development of autoimmune diseases.
The cardiac toxicity of interferon alpha is also well known and uncommon. The mechanism of interferon cardio toxicity is unclear and probably multifactorial. There are no established predisposing factors for interferon cardio toxicity. The secondary effects of interferon described include arrhythmia (atrial fibrillation, sinus bradycardia, atrioventricular block), ischemic cardiomyopathy and cardiomyopathy with the dosage levels used in the treatment of hepatitis C [2] . Myocardial ischemia is mainly caused by cardio toxicity of interferon and antimetabolites [22] . Patients with previous heart disease are probably at higher risk for arrhythmia and ischemic manifestations [1] . Concerning drug toxicity, there have been reported cases of acute pericarditis after the administration of: Hydralazine, procainamide, izoniazid, phenylbutazone, dantrolene, doxorubicin, and penicillin. These situations are extremely rare. Sonnenblick et al [23] demonstrated that the cardiac effects of interferon were not related to the daily dose, cumulative total dose, or period of therapy and cardiac toxicity was reversible following the cessation of the drug therapy. Interferon inhibits cardiac cell function in vitro [24] . The Naranjo adverse drug reactions (ADR) Probability Scale [25] is a validated tool used to determine the like lihood that the adverse drug reaction is caused by the implicated medication. The Naranjo algorithm requires a series of questions to be answered and scored. The total calculated score indicates the likelihood of causing an adverse drug reaction. Popescu et al [11] used the Naranjo ADR Probability Scale to evaluate the correlation of pericarditis with interferon administration. This scale indicated a very probable association. Treatment of interferoninduced cardio toxicity rests mainly on early recognition and drug discontinuation. There is a high degree of individual variation in toxicity, but most adverse events are reversible upon cessation of the drug [8] . In the present study, 4 of 9 patients were treated with prednisone and 4 with NSAIDs.
Chronic hepatitis C viral (HCV) infection and treatment with interferon are both associated with serological and clinical autoimmune manifestations [26, 27] . The serological immune response to HCV infection may include the development of cryoglobulinemia, rheumatoid factor, anti cardiolipin, antinuclear, antiliverkidneymicrosome 1 and antismooth muscle antibodies. Serological autoimmune manifestations were explained by the lymphotropism of HCV and the polyclonal activation of B cells. Interferon based treatment of HCV infection may precipitate or exacerbate the associated autoimmune disease. Classically, type Ⅱ Cryoglobulinaemia, glomerulonephritis and thy roiditis are described.
Interferon related pericarditis still remains uncertain. There may be two mechanisms for pericarditis, one is autoimmune and the other is cardio toxicity. Treatment of interferon related pericarditis rests mainly on early recognition and drug discontinuation. Interferon related pericarditis was treated with steroid and/or NSAIDs.
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Background
When the authors examine a new unusual patient that the authors have never treated before, the authors need to research previous case reports. However, the case report is individual. The authors need to know what kind of examinations they need and what kind of treatments they need as soon as possible. This manuscript aimed to summarize those previous case reports concerning interferon related pericarditis.
Research frontiers
There may be two mechanisms for interferon related pericarditis, one is autoimmune and the other is cardio toxicity. Treatment of interferon related pericarditis rests mainly on early recognition and drug discontinuation. Interferon related pericarditis was treated with steroid and/or nonsteroidal antiinflammatory drugs.
Innovations and breakthroughs
This is the first article that was summarized interferon related pericarditis.
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